Northwestern University Feinberg School of Medicine
Skip to main content

2020 American Society of Hematology (ASH) Annual Meeting

Research findings from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting, to be held virtually Dec. 5 – 8, 2020.* With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.

Use #ASH20 to follow and share on Twitter.

Following the ASH Presidential Symposium on Tues., Dec. 8, Jane Winter, MD, will begin successive one-year terms as president - elect and president. An ASH member for more than 30 years, Dr. Winter is a professor of Medicine in the Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine, and currently serves as vice president of ASH. Her research focus includes clinical and biological markers of prognosis in diffuse large B-cell lymphoma, as well as clinical trials and translational research with novel agents for non-Hodgkin and Hodgkin lymphoma.

As leaders in the research and treatment of blood cancers, Lurie Cancer Center and Northwestern Medicine’s physicians and scientists will present exciting new research and important clinical findings throughout the meeting. Presenting authors and investigators who will be leading sessions include:

Saturday, December 5

10:45 AM CST

Barbara Pro, MD

Abstract 44 

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial

2:15 PM CST

Alexis Thompson, MD

Abstract 154 

Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

2:45 PM CST

Adam Yuh Lin, MD, PhD

Abstract 174 

In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model

4:30 PM CST

Yazan Numan, MD

Abstract 262 

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

9:00 AM – 5:30 PM CST

William Pearse, MD

Abstract 1204

Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review

Abstract 1621

Perceptions of Financial and Psychosocial Burden Among Patients with Hematologic Malignancies Treated with Novel Oral Antineoplastic Agents

9:00 AM – 5:30 PM CST

Carlos Galvez, MD

Abstract 1190

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

Sunday, December 6

5:15 PM CST

Brady L. Stein

Abstract 484

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

9:00 AM – 5:30 PM CST

Jessica Altman, MD

Abstract 1958

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

9:00 AM – 5:30 PM CST

Carlos Galvez, MD

Abstract 2559

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience

9:00 AM – 5:30 PM CST

Jenn Miller, PharmD

Abstract 1951

Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens

Monday, December 7

3:30 PM CST

Alexis Thompson, MD

Abstract 677 

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

9:00 AM – 5:30 PM CST

Reem Karmali, MD

Abstract 3031

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

*Friday, December 4

10:00 AM CST

Jessica Altman, MD, and William Pearse, MD

Abstract 217 

Press Briefing on Disparities in Health Care: Diversity, Equity and Inclusion (DEI)

The Role of Structural Violence in Acute Myeloid Leukemia Outcomes